Provided by Tiger Fintech (Singapore) Pte. Ltd.

CMS

7.960
-0.070-0.87%
Volume:7.27M
Turnover:57.84M
Market Cap:19.42B
PE:7.58
High:8.140
Open:8.020
Low:7.860
Close:8.030
Loading ...

China Medical System Holdings - Unit Entered Into Exclusive Commercialization Agreemen With Atom Therapeutics

THOMSON REUTERS
·
02 Dec 2024

China Medical System's CMS-D005 Approved for Clinical Trial by Chinese Regulator

MT Newswires Live
·
28 Nov 2024

BRIEF-China Medical System Gets Approval Of Drug Clinical Trials For Glucagon Receptor CMS-D005

Reuters
·
27 Nov 2024

China Medical System - Approval of Drug Clinical Trials for Glucagon Receptor CMS-D005 From Nmpa China

THOMSON REUTERS
·
27 Nov 2024

Investors in China Medical System Holdings (HKG:867) have unfortunately lost 31% over the last three years

Simply Wall St.
·
12 Nov 2024

China Medical System's Vitiligo Cream Gets NDA from Hong Kong Authorities, Shares Slide 3%

MT Newswires Live
·
06 Nov 2024

BRIEF-China Medical System Says New Drug Application Of Ruxolitinib Phosphate Cream Approved

Reuters
·
06 Nov 2024

China Medical System - New Drug Application of Ruxolitinib Phosphate Cream for Vitiligo Approved by Pharmacy & Poisons Board of Hong Kong

THOMSON REUTERS
·
05 Nov 2024

Insiders of China Medical System Holdings Limited (HKG:867) must be disappointed as stock fell 4.7% after recent purchases

Simply Wall St.
·
22 Oct 2024

Chinese Regulator Approves China Medical System's New Drug Application for Ruxolitinib Phosphate Cream

MT Newswires Live
·
25 Sep 2024

Stock Track | CMS Stock Soars 8% as New Drug Application Accepted by NMPA

Stock Track
·
24 Sep 2024

BRIEF-China Medical System Says New Drug Application Accepted By NMPA

Reuters
·
24 Sep 2024

China Medical System: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China

THOMSON REUTERS
·
24 Sep 2024

China Medical System Holdings - New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted by Nmpa

THOMSON REUTERS
·
24 Sep 2024